741 related articles for article (PubMed ID: 33181454)
1. The effect of favipiravir on QTc interval in patients hospitalized with coronavirus disease 2019.
Çap M; Bilge Ö; Işık F; Burak C; Karagöz A; İnci Ü; Akyüz A; Aslan B; Altıntaş B; Altındağ R; Kaya İ; Adıyaman MŞ; Süleymanoğlu M; Kaya Ş; Baysal E
J Electrocardiol; 2020; 63():115-119. PubMed ID: 33181454
[TBL] [Abstract][Full Text] [Related]
2. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Effect of Favipiravir on QT Intervals in COVID-19 Patients with and without Diabetes Mellitus.
Dogan M; Baykiz D; Yilmaz I; Hacioglu Kasim FB; Bilir BE; Bilir B
J Coll Physicians Surg Pak; 2024 Jun; 34(6):659-666. PubMed ID: 38840347
[TBL] [Abstract][Full Text] [Related]
4. Effects of hydroxychloroquine and favipiravir on clinical course in outpatients with COVID-19.
Ömeroğlu ŞK; Temel F; Altun D; Öztop B
Turk J Med Sci; 2021 Dec; 51(6):2827-2834. PubMed ID: 34165273
[TBL] [Abstract][Full Text] [Related]
5. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
Guner R; Hasanoglu I; Kayaaslan B; Aypak A; Akinci E; Bodur H; Eser F; Kaya Kalem A; Kucuksahin O; Ates I; Bastug A; Tezer Tekce Y; Bilgic Z; Gursoy FM; Akca HN; Izdes S; Erdem D; Asfuroglu E; Hezer H; Kilic H; Cıvak M; Aydogan S; Buzgan T
J Infect Public Health; 2021 Mar; 14(3):365-370. PubMed ID: 33647553
[TBL] [Abstract][Full Text] [Related]
6. Outcome of noncritical COVID-19 patients with early hospitalization and early antiviral treatment outside the ICU.
Çalık Başaran N; Uyaroğlu OA; Telli Dizman G; Özışık L; Şahin TK; Taş Z; İnkaya AÇ; Karahan S; Alp Ş; Alp A; Metan G; Zarakol P; Sain Güven G; Öz ŞG; Topeli A; Uzun Ö; Akova M; Ünal S
Turk J Med Sci; 2021 Apr; 51(2):411-420. PubMed ID: 32718127
[TBL] [Abstract][Full Text] [Related]
7. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
Manosuthi W; Jeungsmarn S; Okada P; Suwanvattana P; Wongboot W; Thawornwan U; Charoenpong L; Wiboonchutikul S; Uttayamakul S; Pongpirul WA; Wachirapan A; Warachit P
Jpn J Infect Dis; 2021 Sep; 74(5):416-420. PubMed ID: 33518623
[TBL] [Abstract][Full Text] [Related]
8. Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study.
Ucan A; Cerci P; Efe S; Akgun H; Ozmen A; Yagmuroglu A; Bilgin M; Avci D
Virol J; 2021 May; 18(1):102. PubMed ID: 34034765
[TBL] [Abstract][Full Text] [Related]
9. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Corrected QT Interval Changes Among Patients Treated for COVID-19 Infection During the Early Phase of the Pandemic.
Rubin GA; Desai AD; Chai Z; Wang A; Chen Q; Wang AS; Kemal C; Baksh H; Biviano A; Dizon JM; Yarmohammadi H; Ehlert F; Saluja D; Rubin DA; Morrow JP; Avula UMR; Berman JP; Kushnir A; Abrams MP; Hennessey JA; Elias P; Poterucha TJ; Uriel N; Kubin CJ; LaSota E; Zucker J; Sobieszczyk ME; Schwartz A; Garan H; Waase MP; Wan EY
JAMA Netw Open; 2021 Apr; 4(4):e216842. PubMed ID: 33890991
[TBL] [Abstract][Full Text] [Related]
11. Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic: Implications for QT Interval Monitoring.
Ramireddy A; Chugh H; Reinier K; Ebinger J; Park E; Thompson M; Cingolani E; Cheng S; Marban E; Albert CM; Chugh SS
J Am Heart Assoc; 2020 Jun; 9(12):e017144. PubMed ID: 32463348
[TBL] [Abstract][Full Text] [Related]
12. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.
Kaptein SJF; Jacobs S; Langendries L; Seldeslachts L; Ter Horst S; Liesenborghs L; Hens B; Vergote V; Heylen E; Barthelemy K; Maas E; De Keyzer C; Bervoets L; Rymenants J; Van Buyten T; Zhang X; Abdelnabi R; Pang J; Williams R; Thibaut HJ; Dallmeier K; Boudewijns R; Wouters J; Augustijns P; Verougstraete N; Cawthorne C; Breuer J; Solas C; Weynand B; Annaert P; Spriet I; Vande Velde G; Neyts J; Rocha-Pereira J; Delang L
Proc Natl Acad Sci U S A; 2020 Oct; 117(43):26955-26965. PubMed ID: 33037151
[TBL] [Abstract][Full Text] [Related]
13. EFFECTS OF HYDROXYCHLOROQUINE PLUS FAVIPIRAVIR TREATMENT ON THE CLINICAL COURSE AND BIOMARKERS IN HOSPITALIZED COVID-19 PATIENTS WITH PNEUMONIA.
Delen LA; Gok A; Kasapoglu US; Cagasar O; Gok Z; Berber N; Derya S; Tetik B
Acta Clin Croat; 2022 Nov; 61(3):403-411. PubMed ID: 37492367
[TBL] [Abstract][Full Text] [Related]
14. Corrected QT interval in hospitalized patients with coronavirus disease 2019: Focus on drugs therapy.
Ding J; Liu W; Guan H; Feng Y; Bao Y; Li H; Wang X; Zhou Z; Chen Z
Medicine (Baltimore); 2021 Jul; 100(28):e26538. PubMed ID: 34260531
[TBL] [Abstract][Full Text] [Related]
15. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
[TBL] [Abstract][Full Text] [Related]
16. Effect of triple antimicrobial therapy on electrocardiography parameters in patients with mild-to-moderate coronavirus disease 2019.
Uğurlu Ilgın B; Akbulut Koyuncu İM; Kızıltunç E
Anatol J Cardiol; 2021 Mar; 25(3):184-190. PubMed ID: 33690133
[TBL] [Abstract][Full Text] [Related]
17. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.
Koh HM; Chong PF; Tan JN; Chidambaram SK; Chua HJ
J Clin Pharm Ther; 2021 Jun; 46(3):800-806. PubMed ID: 33768612
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
Dabbous HM; El-Sayed MH; El Assal G; Elghazaly H; Ebeid FFS; Sherief AF; Elgaafary M; Fawzy E; Hassany SM; Riad AR; TagelDin MA
Sci Rep; 2021 Mar; 11(1):7282. PubMed ID: 33790308
[TBL] [Abstract][Full Text] [Related]
19. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
Seyhan AU; Doganay F; Yilmaz E; Topal NP; Ak R
J Coll Physicians Surg Pak; 2020 Oct; 30(10):153-157. PubMed ID: 33291194
[TBL] [Abstract][Full Text] [Related]
20. Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.
Jiménez-Jáimez J; Macías-Ruiz R; Bermúdez-Jiménez F; Rubini-Costa R; Ramírez-Taboada J; Flores PIG; Gallo-Padilla L; García JDM; García CM; Suárez SM; Molina CF; López MÁ; Tercedor L
Sci Rep; 2020 Dec; 10(1):21417. PubMed ID: 33293554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
